The Clinical Application Of Serum Osteoprotegerin Concentration In Human Prostate Cancer

Objective:In order to understand the clinical value of serum OPG in differential diagnosing prostate cancer from benign prostate hyperplasia as well as evaluation of the bone metastases in prostate cancer patients,the differences of serum OPG levels were analyzed between patients with prostate cancer and benign prostate hyperplasia combined with clinical data,such as Gleason score,serum PSA,prostate volume and ECT bone scan.Methods:We analyzed 65 prostate cancer and benign prostate hyperplasia patients who were diagnosed and treated in our hospital from September 2006 to March 2008.Of 65 patients,there were 40 cases of prostate cancer with the age from 48 to 89 years old,and the mean of 68.2;and 25 cases of benign prostate hyperplasia with the age from 52 to 86, and the mean of 71.6.The concentration of the serum OPG was determined by ELISA. The clinical data of Gleason score,ECT bone scan,serum PSA and prostate volume were collected.The statistical significance of serum OPG difference between prostate cancer and benign prostate hyperplasia patients was evaluated using the SPSS 10.0 software.The linear correlation method was used to determine the relation between serum OPG and serum PSA as well as ECT bone scan and prostate volume.The serum OPG levels among different Gleason score groups were analyzed by SNK-test.Results:Serum OPG in patients with prostate cancer was 14900.19±5168.65pg/ml, which is significantly different from 10390.94±4649.77pg/ml with benign prostate hyperplasia(P=0.001,t = 3.553).The patients with bone metastases have significantly higher serum OPG level of 16237.19±5144.26 pg/ml than patients without bone metastases,whose value were 12123.32±4136.50 pg/ml(P = 0.016,t = 2.513).There was no obvious correlation between serum OPG and PSA in patients with prostate cancer(r =0.221,P=0.171),as well as prostate volume(r=0.221,P=0.171).There was also no statistically significant correlation between serum OPG and Gleason score in patients with prostate cancer(P=0.565)。Conclusions:1.The serum OPG has the assistant differential diagnostic value between the prostate cancer and benign prostate hyperplasia.2.The serum OPG has the important value in prediction of bone metastases in prostate cancer patients.3.No correlation between the serum OPG and the serum PSA as well as the prostate volume in prostate cancer patients was observed.4.No obvious relevance between the serum OPG and the Gleason score in prostate cancer patients was observed...